Bendamustin in combination with Fludarabin for the treatment of refractory or relapsed low-grade lymphoma - A multicenter phase I/II trial of the East German study group for hematology and oncology (OSHO).

被引：0
|
作者：
Koenigsmann, MP [1 ]
Knauf, WU [1 ]
Herold, M [1 ]
Franke, A [1 ]
机构：
[1] Otto Von Guericke Univ, Magdeburg, Germany
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2543
引用
收藏
页码：607A / 607A
页数：1
相关论文
共 50 条
  • [41] Immunochemotherapy (R-MCP) prolongs survival in advanced follicular lymphoma -: 50 months up-date of a phase III study of the east German study group hematology and oncology (OSHO#39)
    Herold, M.
    Haas, A.
    Doerken, B.
    Neser, S.
    Al Ali, K. H.
    Neubauer, A.
    Doelken, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 180 - 181
  • [42] Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: A phase I/II study.
    Berenson, J
    Yang, H
    Swift, R
    Sadler, K
    Vescio, R
    Adams, J
    Schenkein, D
    BLOOD, 2004, 104 (11) : 64A - 64A
  • [43] Phase I/II Multicenter Study of Romidepsin in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Ogura, Michinori
    Maruyama, Dai
    Tobinai, Kensei
    Uchida, Toshiki
    Hatake, Kiyohiko
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Tsukasaki, Kunihiro
    Ishida, Takashi
    Kobayashi, Naoki
    Ishizawa, Kenichi
    Tatsumi, Yoichi
    Kato, Koji
    Kiguchi, Toru
    Ikezoe, Takayuki
    Laille, Eric
    Ro, Tokihiro
    Tamakoshi, Hiromi
    Sakurai, Sanae
    Ohtsu, Tomoko
    BLOOD, 2016, 128 (22)
  • [44] Phase I/II trial of pamidronate and interleukin-2 (IL-2) for relapsed/refractory multiple myeloma (MM) and low-grade non-Hodgkin's lymphoma (NHL).
    Kunzmann, V
    Kelm, K
    Eckstein, S
    Wilhelm, M
    BLOOD, 2000, 96 (11) : 733A - 733A
  • [45] A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517
    Kirschbaum, Mark H.
    Goldman, Bryan H.
    Zain, Jasmine M.
    Cook, James R.
    Rimsza, Lisa M.
    Forman, Stephen J.
    Fisher, Richard I.
    LEUKEMIA & LYMPHOMA, 2012, 53 (02) : 259 - 262
  • [46] Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX)
    Leblond, Pierre
    Tresch-Bruneel, Emmanuelle
    Probst, Alicia
    Neant, Nadege
    Solas, Caroline
    Sterin, Arthur
    Boulanger, Thomas
    Aerts, Isabelle
    Faure-Conter, Cecile
    Bertozzi, Anne-Isabelle
    Chastagner, Pascal
    Entz-Werle, Natacha
    De Carli, Emilie
    Le Deley, Marie-Cecile
    Bouche, Gauthier
    Andre, Nicolas
    CANCERS, 2023, 15 (07)
  • [47] A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma.
    Mehta-Shah, Neha
    Lunning, Matthew Alexander
    Boruchov, Adam M.
    Ruan, Jia
    Nair, Sumithra
    Lynch, Peggy
    Byrne, Regina
    Moskowitz, Alison J.
    Matasar, Matthew J.
    Gerecitano, John F.
    Hamlin, Paul A.
    Leonard, John
    Moskowitz, Craig H.
    Myskowski, Patricia L.
    Querfeld, Christiane
    Nolan, Patrick
    Palomba, Maria Lia
    Straus, David J.
    Zelenetz, Andrew David
    Horwitz, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124)
    Meyers F.J.
    Lew D.
    Lara Jr. P.N.
    Williamson S.
    Marshall E.
    Balcerzak S.P.
    Rivkin S.E.
    Samlowski W.
    Crawford E.D.
    Investigational New Drugs, 1998, 16 (4) : 347 - 351
  • [49] Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124)
    Meyers, FJ
    Lew, D
    Lara, PN
    Williamson, S
    Marshall, E
    Balcerzak, SP
    Rivkin, SE
    Samlowski, W
    Crawford, ED
    INVESTIGATIONAL NEW DRUGS, 1999, 16 (04) : 347 - 351
  • [50] A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma
    Foss, Francine Marie
    Parker, Terri
    ONCOLOGIST, 2018, 23 (04): : 397 - +
12345